Cyclin A and E2F1 overexpression correlate with reduced disease-free survival in node-negative breast cancer patients.

Abstract

These findings suggest that assessment of cyclin A and/or E2F1 expression levels, associated with Ki67, might be useful for a better prognostic evaluation of node-negative breast cancer patients and support the need for further studies to evaluate their suitability for use in the routine clinical management of these patients.